AdvaMed & StartX partnership hopes to bring healthcare innovations to market faster

A new partnership has been signed between the Advanced Medical Technology Association (AdvaMed) and StartX to help bring healthcare innovations to market.

The collaboration will give medtech entrepreneurs within the StartX network access to AdvaMed’s resources and expertise to help them develop and commercialise their products.

StartX is a start-up community for entrepreneurs affiliated with Stanford University. The group’s medical community consists of over 450 entrepreneurs, with more than 180 active companies developing medical devices, diagnostic tests, patient monitoring systems and more.

StartX entrepreneurs are invited to join AdvaMed’s CEO and community of large medtech and diagnostics companies alongside nearly 300 smaller, start-up and early stage companies in the AdvaMed Accel division.  More so, StartX companies in the diagnostics and digital health fields will be given access to resources through AdvaMedDX and the association’s Centre for Digital Health.

“StartX Med has done a remarkable job of advancing incredible innovations that save and improve lives. I’m really excited about this partnership, which gives us, working together, the opportunity to get more of those innovations into doctors’ and patients’ hands,” said Scott Whitaker, AdvaMed president and CEO.  “And through AdvaMed Accel, StartX Med alumni will have access to essential resources, decision makers, and information critical to bringing their life-saving and life-changing innovations to patients.”

"It is with open arms that we welcome AdvaMed as a partner to strengthen the support we are providing to our founders innovating in the biomedical fields,” added Joseph Huang, StartX CEO. “Our community represents the best and brightest founders from Stanford and around the world, including more than 60 tenure-track Stanford Professors translating their research all the way to impacting real patients. With this partnership with AdvaMed, we are sure to improve the time in which it takes these transformative products to reach patients and clinical care worldwide.”